Biocon Arm Collaborate With Civica to Expand Insulin Aspart in the USA

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Limited, is a pioneering, fully integrated global biosimilars company dedicated to transforming healthcare and enhancing lives. Leveraging its ‘lab to market’ expertise, BBL delivers high-quality biosimilars to millions of patients across 120+ countries, ensuring affordable access to life-saving treatments.

Collaboration with Civica

Biocon Biologics Ltd (BBL), in collaboration with Civica, Inc. (Civica), a not-for-profit generic drug and pharmaceutical company founded in 2018 to tackle critical drug shortages and affordability challenges, today announced a strategic partnership to improve access to Insulin Aspart in the United States.

Under this agreement, Biocon Biologics will supply Insulin Aspart drug substance to Civica, which will manufacture the final drug product—a rapid-acting insulin analogue—at its state-of-the-art facility in Petersburg, Virginia. Following the completion of development and clinical trials, Civica will commercialise the medicine for patients across the United States. Notably, this partnership does not involve any technology transfer.

Statement from Biocon Biologics Ltd

“As a fully integrated global biologics leader, Biocon Biologics is uniquely positioned to drive commercial success through tailored go-to-market strategies that create enduring value for all stakeholders.” 

They further added, “Our collaboration with Civica exemplifies this commitment, enabling us to expand patient access to Insulin Aspart in the United States while reaffirming our dedication to addressing the growing needs of individuals living with diabetes. Together, we are working to ensure that more patients can obtain high-quality, affordable insulin.”

Share Price Performance

At 10:49 AM on March 7, 2025, Biocon Ltd. shares traded  0.98% up at ₹336.25 per share on the NSE.

Conclusion

In order to meet vital patient needs, Biocon Biologics and Civica have partnered strategically to improve Insulin Aspart’s accessibility and affordability in the US. The collaboration strengthens a shared goal to provide affordable, life-saving insulin to patients who need it most by utilising Civica’s dedication to lowering drug shortages and Biocon Biologics’ experience with biosimilars.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.